Innovative payment schemes are bilateral or multilateral agreements that support medical technologies and procedures that do not fit well with or meet the criteria for the existing reimbursement and funding frameworks.
France is the leading European country in innovative payment schemes supporting evidence generation or early adoption of medical technologies. One such scheme is Innovation Funding (Forfait Innovation) for Medical Technologies, which provides early support for breakthrough innovation and bridges serious evidence gaps simultaneously. Forfait Innovation allows manufacturers to apply to the Ministry of Health and HAS for support of a government-co-sponsored study of novel medical devices, procedures, and IVD tests.
Our latest White Paper provides a comprehensive overview of the Innovation Funding (Forfait Innovation) program. It describes the scheme’s objectives, eligibility criteria, funding structure, and the decision-making process with regulated timelines. It also outlines the roles of stakeholders, clinical and economic evidence requirements, and the outcomes of applications since the program’s launch in 2015. In addition, this document presents a case study of the METAglut1 test, illustrating the pathway from Innovation Funding to permanent reimbursement inclusion under NABM.
This resource offers manufacturers a clear roadmap for navigating the Innovation Funding framework, securing support for evidence generation, and making a significant step forward with the market access of their cutting-edge medical solutions in France.
Request White Paper
Request analytical White Paper and advance your understanding of European market access for medical devices